Genmab A/S : Interim Report for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024


May 2, 2024 Copenhagen, Denmark;


Interim Report for the First Quarter Ended...

Related Keywords

Copenhagen ,Køavn ,Denmark ,China ,Japan ,Valby ,Hovedstaden ,Japanese ,Genmab Duobody ,Tivdak Genmab ,Andrew Carlsen ,Informationfor Tivdak ,Genmab Abbvie ,Marisol Peron ,Abbvie Inc ,Society Of Gynecologic Oncology ,Exchange Commission ,Pfizer Inc ,European Medicines Agency ,Pfizer ,Us National Comprehensive Cancer Network ,Company Announcement ,Medarex Inc ,Janssen Biotech Inc ,Profoundbio Inc ,Pipeline Including Further Development For Approved Medicines ,Ministry Of Health ,Drug Administration ,Halozyme Therapeutics Inc ,Global Communications Corporate Affairs ,Zai Lab ,Genmab Announces Financial Results ,First Quarter ,First Quarter Ended March ,Priority Review ,Biologics License Application ,Prescription Drug User Fee Act ,Janssen Biotech ,Chief Executive Officer ,Performance First Quarter ,Novartis Pharma ,Jacobsens Vej ,Announces Financial Results ,Senior Vice President ,Global Communications ,Vice President ,Investor Relations ,Net Product Sales ,Collaboration Revenue ,Product Sales ,Operating Expenses Range ,Product Sales Range ,Gross Profit Range ,Currency Hedge ,Halozyme Therapeutics ,Own Medicines ,Initiate Phase ,Leading Integrated Biotech ,Nasdaq Copenhagen ,Including Further Development ,Approved Medicines ,European Summary ,Product Characteristicsfor ,Japan New Drug Application ,Annual Meeting ,Japanese Society ,Medical Oncology ,Zai Lab Limited ,Comprehensive Cancer Network ,Clinical Practice Guidelines ,Vaginal Cancer ,Gynecologic Oncology ,Markets ,